Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A fixed-dose combination of three pharmaceutical agents: ramipril, an angiotensin-converting enzyme (ACE) inhibitor; amlodipine, a calcium channel blocker; and atorvastatin, a statin. This combination is primarily used to treat hypertension (high blood pressure) and to reduce cardiovascular risk in patients with coexisting dyslipidemia. Ramipril lowers blood pressure by inhibiting the conversion of angiotensin I to angiotensin II, leading to vasodilation. Amlodipine relaxes vascular smooth muscle by blocking L-type calcium channels, further reducing blood pressure. Atorvastatin inhibits HMG-CoA reductase in the liver, lowering LDL cholesterol and triglycerides while raising HDL cholesterol. Together, these agents address both elevated blood pressure and abnormal lipid profiles to reduce overall cardiovascular risk[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ramipril + amlodipine + atorvastatin.